Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Sponsor: Ohio State University Comprehensive Cancer Center
Condition: Chronic Lymphocytic Leukemia, Ibrutinib Resistance
NCT03513562
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.